Recall On Lisinopril 2025. It’s said the lisinopril was distributed nationwide throughout the u.s. The fda will also determine the public hazard assessment and a recall classification will be published in the enforcement report.
The recall is voluntary, and stems from the tablets containing higher levels of nitrosamines, which pose a cancer risk, although pfizer said in a news release “there is no. National data from 2025 suggest that 120 million americans, or nearly half of all u.s.